Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Wednesday

Praxis Precision Medicines (NASDAQ:PRAX) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 6th. Analysts expect Praxis Precision Medicines to post earnings of ($2.01) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.38) by $0.64. Praxis Precision Medicines had a negative return on equity of 61.47% and a negative net margin of 6,987.01%. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.44 million. On average, analysts expect Praxis Precision Medicines to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Praxis Precision Medicines Stock Up 2.4 %

Shares of PRAX traded up $1.68 during trading hours on Tuesday, reaching $71.70. The company’s stock had a trading volume of 64,734 shares, compared to its average volume of 272,698. The company has a 50 day moving average of $62.94 and a two-hundred day moving average of $53.41. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -6.77 and a beta of 2.67. Praxis Precision Medicines has a 1-year low of $13.01 and a 1-year high of $75.73.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PRAX. Wedbush boosted their price target on shares of Praxis Precision Medicines from $40.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday, September 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $145.00 price target on shares of Praxis Precision Medicines in a research note on Tuesday, September 3rd. Oppenheimer boosted their price target on Praxis Precision Medicines from $143.00 to $163.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Guggenheim raised their price objective on shares of Praxis Precision Medicines from $155.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $145.67.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.